As a new decade dawns, AMCP is preparing for the twists and turns of an uncertain first year. With health care a top issue in this year’s presidential campaigns, drug pricing a favorite target, and biosimilar use poised to expand, seeing where this year will lead requires much more than “2020” vision.
AMCP CEO Blog: With PA so often misunderstood, perhaps we need to do a better job of explaining this tool to the general public. For example, we might provide an example of how PAs are applied to opioids as additional safeguards to ensure their appropriate use. Or how a PA might be applied to botulinum toxin to ensure the prescription is for medical, rather than cosmetic, purposes.
By AMCP CEO Susan A. Cantrell, RPh, CAE • 11/13/19
AMCP CEO Blog: We live in an interconnected world where the marketplace for all things is global. But we must also make sure the global system works for the benefit of the patients we serve. That includes taking steps to ensure the long-term stability and integrity of our critical pharmaceutical supply chain.
AMCP CEO Address: AMCP CEO Susan A. Cantrell, RPh, CAE addressed the AMCP 2019 Annual Meeting on March 26, laying out how AMCP is prepared to meet the challenges of today’s complex health care system. The following is a lightly edited transcript of that address.